Advertisement

Topics

BMS’ Opdivo and Yervoy combo gets FDA approval for firstline RCC

02:14 EDT 17 Apr 2018 | Pharmaceutical Business Review

The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb’s (BMS) combination of immuno-oncology drugs Opdivo (nivolumab) and Yervoy (ipilimumab) as first-line treatment for patients with a type of advanced renal cell carcinoma (RCC), or kidney cancer.

Original Article: BMS’ Opdivo and Yervoy combo gets FDA approval for firstline RCC

NEXT ARTICLE

More From BioPortfolio on "BMS’ Opdivo and Yervoy combo gets FDA approval for firstline RCC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...